Infectious Disease Therapeutics Market Share Analysis Report, 2022-2030
The global Infectious Disease Therapeutics market size was estimated at USD 115 billion in 2021 and is expected to surpass around USD 167 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 4.23% during the forecast period 2022 to 2030.
Rising prevalence of infectious ailments, increasing expenditure to boost the penetration rate of treatments of these diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs are likely to be the factors responsible for the growth of this market.
Also, the market is likely to witness the patent expiration of many drugs during the forecast period. The expiry of patents results in the availability of generic drugs, which have the same drug constitution as branded drugs but are available at a very low price. Also, physicians prescribe these drugs to patients as they are cost-effective. Furthermore, a positive reimbursement scenario that covers the diagnosis and treatments of these disorders is expected to propel the market growth.
Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.
In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.
North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.
Report Scope of the Infectious Disease Therapeutics Market
|
Report Coverage |
Details |
|
Market Size in 2022 |
USD 119.87 Billion |
|
Market Size by 2030 |
USD 167 Billion |
|
Growth Rate from 2022 to 2030 |
CAGR of 4.23% |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Mode of Treatment, Target Organism, Infection Type, Distribution Channel and Geography |
|
Companies Mentioned |
Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), Merck & Co. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca (U.K), Mylan N.V. (U.S.), Novartis AG (Switzerland), Sanofi (France) |
Segment Insights
Treatment Insights
On the basis of mode of treatment, the segment of drug has emerged as the fastest growing market owing to its largest share in the global economy. Increasing demand for advanced drugs in the market has helped in this segment to record a considerable revenue over the period of time and it's foreseen to continue its growth in a similar fashion during the future as well. The huge number of people belonging to the geriatric population has emerged as a major opportunity for the segment of drugs as it is the most common line of treatment opted by these people. The availability of medicines over the counter has also proved to be a major opportunity for the growth of the drug segment. Increasing disposable income available with the people has enabled them to opt for advanced drugs available in the market for the purpose of treatment. The other segment which has been discussed under this category includes vaccines which has become a common entity after the birth of a child to the period up till when new diseases keep on emerging into the market along with their vaccinations.
Target Organism Insights
On the basis of target organism, the segment of antibacterial has emerged as the largest market due to its significant share in the global economy. The contribution of the anti-bacterial segment is expected to grow further at a faster rate during the future as well. The increasing prevalence of diseases which spread through the mode of bacteria has boosted the market for the antibacterial segment to a great extent. Increasing prevalence of diseases such as hepatitis A, influenza, tuberculosis, HIV and hepatitis C Merged as a major opportunity for the growth of the anti-bacterial segment in the current market. Increasing disposable income available with the people has emerged as a major opportunity for the sales and demand of advanced antibacterial drugs in the market.
Infection Type Insights
On the basis of infection type, the segment of bacterial infection has emerged as the fastest growing market over the period of time and is expected to show a tremendous boost during the future period as well. The increasing research and development programs conducted by the key market players with a view to introduce innovative medicines that are technologically advanced has helped the segment of bacterial infection to record a considerable growth over the period of time. The huge number of people who suffer with bacterial infection has also emerged as a major opportunity for the growth of the market. The weekend immunity system of the people provides a great opportunity for the bacteria to spread the infectious diseases and hence a considerable growth is recorded over the period of time.
Distribution Channel Insights
On the basis of distribution channel, the segment of hospitals has emerged as the fastest growing market as it proves to be the primary center where a patient shows up first when they are infected buy an infection and hence this sector has recorded a considerable revenue over the period of time. The huge number of people visiting the hospital sector on a daily basis for treating infectious diseases has also proved to be a major growth factor for the market. Dream basement policies and other facilities provided by the hospital sector through the insurance companies emerges as an attractive opportunity for the growth of the market. A number of different facilities are available in the hospital sector which prevents the patient from running to different centers which emerges as another opportunity for the growth of the market.
Regional Insights
North America dominated the market in 2021 with a revenue share of around 45.6%. Increasing prevalence of such disorders and favorable reimbursement scenario are key factors likely to propel the demand for infectious disease therapeutics in the region. Furthermore, the presence of a large number of manufacturers in the U.S. and increasing numbers of clinical trials for the development of new treatment drugs are expected to contribute to the large market share held by this region. Major factors that are likely to propel the growth of this market include the increasing rate of treatment & diagnosis of infectious diseases and rising funding activities to support the development of new drugs.
Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. High prevalence of HIV, malaria, TB, and other infections; increasing incidence of these conditions; and rising expenditure on the prevention and diagnosis of infectious diseases are likely to be the key factors responsible for the growth of this market. Furthermore, increasing the focus of governments of various countries on the prevention of infections and on raising funds to increase the adoption of treatments for infectious diseases are expected to further propel the market during the forecast period.
Some of the prominent players in the Infectious Disease Therapeutics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Infectious Disease Therapeutics market
By Mode of Treatment
By Target Organism
By Infection Type
By Distribution Channel
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Infectious Disease Therapeutics Market Study:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Infectious Disease Therapeutics Market
5.1. COVID-19 Landscape: Infectious Disease Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Infectious Disease Therapeutics Market, By Mode of Treatment
8.1. Infectious Disease Therapeutics Market, by Mode of Treatment, 2022-2030
8.1.1. Vaccines
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Drugs
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Infectious Disease Therapeutics Market, By Target Organism
9.1. Infectious Disease Therapeutics Market, by Target Organism e, 2022-2030
9.1.1. Antifungal
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Antiviral
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Antibacterial
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Anti-parasite
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Infectious Disease Therapeutics Market, By Infection Type
10.1. Infectious Disease Therapeutics Market, by Infection Type, 2022-2030
10.1.1. Viral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parasitic
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Fungal
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Bacterial
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Infectious Disease Therapeutics Market, By Distribution Channel
11.1. Infectious Disease Therapeutics Market, by Distribution Channel, 2022-2030
11.1.1. Clinic
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Avastin
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Infectious Disease Therapeutics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.1.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.1.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Pfizer Inc. (U.S.)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. GlaxoSmithKline plc. (U.K)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck & Co. (U.S.)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd (Switzerland)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca (U.K)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Mylan N.V. (U.S.)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novartis AG (Switzerland)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sanofi (France)
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers